RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-Efectiveness of Delayed-Release Dimethyl Fumarate Compared to Glatiramer Acetate and Fingolimod for the Treatment of Relapsing-Remiting Multiple Sclerosis
Mauskopf, J., Fay, M., Iyer, R., & Livingston, T. (2014). Cost-Efectiveness of Delayed-Release Dimethyl Fumarate Compared to Glatiramer Acetate and Fingolimod for the Treatment of Relapsing-Remiting Multiple Sclerosis. Value in Health, 17(3), A60-A61.
